AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
270.54B
Market cap270.54B
Price-Earnings ratio
24.66
Price-Earnings ratio24.66
Dividend yield
1.82%
Dividend yield1.82%
Average volume
2.07M
Average volume2.07M
High today
$177.47
High today$177.47
Low today
$174.06
Low today$174.06
Open price
$176.14
Open price$176.14
Volume
2.00M
Volume2.00M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$153.41
52 Week low$153.41

Stock Snapshot

AstraZeneca(AZN) stock is priced at $174.30, giving the company a market capitalization of 270.54B. It carries a P/E multiple of 24.66 and pays a dividend yield of 1.82%.

On 2026-11-21, AstraZeneca(AZN) stock traded between a low of $174.06 and a high of $177.47. Shares are currently priced at $174.30, which is +0.1% above the low and -1.8% below the high.

AstraZeneca(AZN) shares are trading with a volume of 2M, against a daily average of 2.07M.

During the past year, AstraZeneca(AZN) stock moved between $153.41 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $153.41 at its lowest and $212.71 at its peak.

AZN News

Benzinga 2d
AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples

Tempus AI Inc. (NYSE:TEM) and AstraZeneca Plc. (NASDAQ:AZN) on Monday amended their master services agreement, extending the partnership through Dec. 31, 2031,...

AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples
TipRanks 2d
AstraZeneca Advances Real-World Cancer Study in Germany

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s GRACE-DE study, officially titled “Prospective, Obs...

Seeking Alpha 2d
AstraZeneca wins FDA priority review for gastric cancer therapy

AstraZeneca (AZN) announced on Thursday that the Food and Drug Administration accepted and issued a priority review for its marketing application for its gastri...

AstraZeneca wins FDA priority review for gastric cancer therapy

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
9.1%
Sell
9.1%

More AZN News

TipRanks 2d
Tempus AI’s Expanded AstraZeneca Collaboration Strengthens Growth Outlook; $85 Price Target Unchanged

Tempus AI, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rati...

TipRanks 2d
AstraZeneca’s BLA for Sone-Ve accepted, granted Priority Review in US

AstraZeneca’s (AZN) Biologics License Application, BLA, for sonesitatug vedotin, Sone-Ve, has been accepted and granted Priority Review in the US for the 2nd an...

TipRanks 3d
AstraZeneca Expands Lokelma Evidence With New India Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca plc is evaluating Lokelma in Indian adults with mild...

TipRanks 3d
Tempus AI and AstraZeneca Extend Strategic Services Agreement

Tempus AI, Inc. Class A ( (TEM) ) just unveiled an announcement. On November 16, 2026, Tempus AI and AstraZeneca entered a fifth amendment to their master serv...

Zacks 3d
The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial

Chicago, IL – November 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the...

The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
TipRanks 4d
Clever Culture Systems Reports APAS Customer Growth and Market Expansion

LBT Innovations Limited ( (AU:CC5) ) has shared an announcement. Clever Culture Systems supplies APAS automated culture-plate reading technology for pharmaceut...

Benzinga 5d
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies...

AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.